Chemistry:Cinpanemab

From HandWiki

Cinpanemab (INN, USAN; developmental code names BIIB054, NI-202) is an anti-α-synuclein drug acting as a monoclonal antibody against α-synuclein which was under development for the treatment of Parkinson's disease.[1][2] It showed no significant influence on disease progression in a 52-week phase 2 clinical trial.[2] The drug reached phase 2 clinical trials but was discontinued in 2021 due its lack of effectiveness.[1][3][2] It was under development by Biogen.[1]

See also

  • List of investigational Parkinson's disease drugs
  • Prasinezumab

References

  1. ↑ 1.0 1.1 1.2 "Cinpanemab". AdisInsight. Springer Nature Switzerland AG. 4 June 2021. https://adisinsight.springer.com/drugs/800042594. 
  2. ↑ 2.0 2.1 2.2 "Novel Approaches Targeting in α-Synuclein for Parkinson's Disease: Current Progress and Future Directions for the Disease-Modifying Therapies". Brain Disorders (Elsevier BV) 16. 2024. doi:10.1016/j.dscb.2024.100163. ISSN 2666-4593. 
  3. ↑ "Trial of Cinpanemab in Early Parkinson's Disease". N Engl J Med 387 (5): 408–420. August 2022. doi:10.1056/NEJMoa2203395. PMID 35921450. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Cinpanemab&oldid=4244299"